On this eighth day of the fourth month of the 21st century, after a decade of trial, with the last patient randomized more than 29 months ago, and the majority of patients of about 95% patients randomized for almost 36 months, about 50% patients more than 48 months, and a big chunk of patients more than 60 months,
What is talking about is still a publication of blended, blinded data?
I do believe the company is honest in this publication fiasco, but thing has gone unexpected.
The almost yearly spring refreshes, the big day of 1 June 2018 looming large, the good doc's unintentional reveal of final analysis is still on going and the results have not yet been reported,
Yet, people in this board are still taking about that damned publication (according to dear leader Linda Powers), the damned shareholder vote for increasing share counts, the order of how things or news should come from the perspective of great military tactics...
I am expecting topline data because that's only reasonable and normal thing to do. Unless, data may be not a homerun, let alone additional home run, so that dear Linda Powers wants to continue her great game of kicking the can down the road again, dangling a carrot with a different color in the not far distance of Nov 2018, where the last patient will be randomized for whole three years.
Or some kinds of combo trial will finally come to earth, talking about the start day, etc.
Those two would be a danger sign to me.
From my book, the best solution to both the humanity and our share price is to release topline data before 1 June 2018.
That would be a sensible and right thing to do Linda!
[As a side, I would suspect a big chunk of that 12 million or so finance had gone to Cognate, with a big chunk been returned to Linda's control via that so-called management buyout, which we may be able to see from the now outstanding annual report. If that is true, it puts one more reason why she is hated]
